Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
The Journal of Infection
|
December 19, 2017
Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial
Federico Martinón-Torres, Alfonso Carmona Martinez, Róbert Simkó, et al.
Vaccine
|
December 5, 2016
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial
Mildred A Iro, Matthew D Snape, Merryn Voysey, et al.
Vaccine
|
January 30, 2019
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine
Terry Nolan, Maria Elena Santolaya, Ferdinandus de Looze, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
October 18, 2017
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
Manish Sadarangani, Tim Sell, Mildred A Iro, et al.
Pediatrics
|
August 3, 2018
Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function
Federico Martinón-Torres, Ewa Bernatowska, Anna Shcherbina, et al.
The Pediatric Infectious Disease Journal
|
January 13, 2016
Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age
Matthew D Snape, Merryn Voysey, Adam Finn, et al.
JAMA
|
February 10, 2012
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial
Nicoletta Gossger, Matthew D Snape, Ly-Mee Yu, et al.
Open Forum Infectious Diseases
|
November 25, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults
Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Infectious Diseases
|
December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial
Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
Lancet (London, England)
|
August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
Robert C Read, David Baxter, David R Chadwick, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
The Journal of Infection
|
December 19, 2017
Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial
Federico Martinón-Torres, Alfonso Carmona Martinez, Róbert Simkó, et al.
Vaccine
|
December 5, 2016
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial
Mildred A Iro, Matthew D Snape, Merryn Voysey, et al.
Vaccine
|
January 30, 2019
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine
Terry Nolan, Maria Elena Santolaya, Ferdinandus de Looze, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
October 18, 2017
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
Manish Sadarangani, Tim Sell, Mildred A Iro, et al.
Pediatrics
|
August 3, 2018
Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function
Federico Martinón-Torres, Ewa Bernatowska, Anna Shcherbina, et al.
The Pediatric Infectious Disease Journal
|
January 13, 2016
Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age
Matthew D Snape, Merryn Voysey, Adam Finn, et al.
JAMA
|
February 10, 2012
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial
Nicoletta Gossger, Matthew D Snape, Ly-Mee Yu, et al.
Open Forum Infectious Diseases
|
November 25, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults
Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
The Lancet. Infectious Diseases
|
December 8, 2024
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial
Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, et al.
Lancet (London, England)
|
August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
Robert C Read, David Baxter, David R Chadwick, et al.
Page
of 5